MARKET WIREYahoo Finance • 21h ago
Grail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy?Yahoo Finance report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
Why GRAL Stock dropped -6.74% Today — RQD Quant Desk Flash
$133.76 -6.74% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $131.88
GRAIL Inc. (GRAL) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $6.41B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on GRAL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is GRAL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, GRAIL Inc. (NASDAQ: GRAL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $133.76 (-6.74% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, GRAL ranks #211 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does GRAL compare to RDNT and BLLN in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), GRAL carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.0%. By comparison, RDNT (RadNet Inc.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.78B) and BLLN (BillionToOne Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC 2.9%, cap $5.35B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for GRAL?
▼
Per GRAL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001699031), GRAIL Inc. generated $147.2M in revenue (+17.2% YoY), -$408.4M in net income, and -$299.9M in free cash flow against $2.92B in total assets and $154.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $131.89 (-1.40%)🧬 Dilution Drag (+1.64% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D+ · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-1.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GRAL)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY GRAL SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (33% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (26% of score)
Altman Z-Score 7.26 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution6/20 pts (-14 pt drag)
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$139.70-5.1% Next Q
62
Q2 (-2Q)Grade C$132.60+19.1% Next Q
59
Q3 (-1Q)Grade C$157.88-15.3% Next Q
57
CurrentGrade D+$133.76-0.7% Hist 90D α
54
Trajectory: C+ (62) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a GRAL Turnaround Squeeze
While GRAL currently carries a cautious 54/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Big institutional funds and options desks are actively positioning on the bullish side.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($116.44) and Max Pain ($140.45) forces dealer call-delta covering toward $174.80.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $GRAL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “GRAL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why GRAL Stock dropped -6.74% Today — RQD Quant Desk Flash
GRAIL Inc. (GRAL) dropped -6.74% to $133.76, trading at 74% of its 52-week range ($41.5 – $166.48). Stretched risk/reward at current multiples (-18% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 74% of its 52-week range ($41.5 – $166.48) with RSI-14 at 54 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $133.76 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live GRAL Headlines & Catalysts
MARKET WIREThe Motley Fool • 1d ago
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?The Motley Fool report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRECNBC • 1d ago
This buzzy biotech stock is up 60% this year. Cramer's advice on building a stakeCNBC report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
CATALYSTInvesting.com • 1d ago
TD Cowen raises Grail stock price target to $180 on FDA outlookInvesting.com report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETrefis • 1d ago
Who Is Paying For GRAIL’s Cash Burn?Trefis report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingView • 1d ago
GRAIL, Inc. Stock 12‑Month Price Target Raised to $122.1, Implies 13% DownsideTradingView report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance Singapore • 1d ago
GRAIL, Inc. (GRAL) stock price, news, quote and historyYahoo Finance Singapore report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Have Insiders Sold GRAIL Shares Recently?Simply Wall St report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo • 4d ago
GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive GrowthGRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.
RISK WATCHYahoo • 6d ago
GRAIL to Present at the UBS Global Healthcare ConferenceGRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the UBS Global Healthcare Conference in Palm Beach, F
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring GRAL)
- ✓Walkthrough of GRAL's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
GRAL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +140.32%▲ ASCENDING CHANNEL
2026-11-03O $158.9H $158.9L $133.8C $133.8VOL 1.07M
RES: $187.0SUP: $91.53SMA50: $116.4SMA200: $78.89
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
GRAL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
15.7%/yr Implied 5Y Growth
vs. +17.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on GRAL today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for GRAL. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for GRAL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GRAL)
Health Care Rank #211 of 1015
⚔️ RDNT vs GRAL Full Matrix →
1. Head-to-Head Health Care Peer Comparison (GRAL vs. RDNT, BLLN, CON, CDNA)
Industry: Medical Specialities (41 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, GRAIL Inc. (GRAL) ranks #211 by composite RQD confidence (54/100, grade D+) and #140 by equity capitalization ($6.41B). Within this direct 5-issuer industry benchmark cohort, CON leads on earnings valuation at 31.6x trailing P/E, while CON leads on capital efficiency and profitability with 19.7% ROIC and — gross margin. CDNA currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with GRAL at 54/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GRAL
ACTIVE
GRAIL Inc. | D+ | 54/100 | — | — | -18.0% | -6.74% | $6.41B | Benchmark Subject |
| RDNT RadNet Inc. | D+ | 57/100 | — | — | 3.5% | -0.53% | $5.78B | /rdnt-vs-gral → |
| BLLN BillionToOne Inc. | B- | 70/100 | — | 68.3% | 2.9% | -2.57% | $5.35B | /blln-vs-gral → |
| CON Concentra Group Holdings Parent Inc. | C+ | 68/100 | 31.6x | — | 19.7% | -0.12% | $5.15B | /con-vs-gral → |
| CDNA CareDx Inc. | B- | 71/100 | — | — | -8.2% | -1.75% | $4.59B | /cdna-vs-gral → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001699031 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), GRAIL Inc. (GRAL) reported GAAP revenue of $147.2M (+17.2% vs. FY2024 revenue of $125.6M , and +58.1% cumulative change since FY2023) , GAAP net income of -$408.4M, operating cash flow of -$299.0M, and free cash flow of -$299.9M (+48.5% YoY). On the balance sheet, GRAL closed FY2025 with $2.92B in total assets against $154.9M in total debt (Altman Z-Score: 7.26, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $147.2M | -$408.4M | -$299.0M | -$299.9M | $2.92B | $154.9M |
| FY2024 (FY) | 2024-12-31 | $125.6M | -$2.03B | -$577.2M | -$582.4M | $2.98B | $216.0M |
| FY2023 (FY) | 2023-12-31 | $93.1M | -$1.47B | -$595.8M | -$600.0M | $3.90B | $913.6M |
3. GRAL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs GRAL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, GRAIL Inc. (NASDAQ: GRAL) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $133.76 (-6.74% 1D, market cap $6.41B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 6/20. Across 1015 tracked Health Care issuers, GRAL ranks #211 in composite RQD confidence.
How does GRAL compare to RDNT and BLLN in the Health Care sector?
Within the Health Care sector (Medical Specialities), GRAL carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -18.0%. By comparison, RDNT (RadNet Inc.) holds a D+ grade (57/100 RQD, P/E N/A, ROIC 3.5%, cap $5.78B) and BLLN (BillionToOne Inc.) posts a B- grade (70/100 RQD, P/E N/A, ROIC 2.9%, cap $5.35B). Among the 5-stock peer group, CON leads on earnings multiple (31.6x) while CON leads on capital efficiency (19.7% ROIC).
What are the biggest fundamental strengths and SEC risk factors for GRAL?
Per GRAL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001699031), GRAIL Inc. generated $147.2M in revenue (+17.2% YoY), -$408.4M in net income, and -$299.9M in free cash flow against $2.92B in total assets and $154.9M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is GRAL trading relative to its 50-day, 200-day, and 52-week technical levels?
GRAL last traded at $133.76 (-6.74% on volume of 983,307 shares), positioning the stock +14.87% above its 50-day simple moving average ($116.44) and +69.55% above its 200-day simple moving average ($78.89). Across its 52-week range of $41.50 to $166.48, GRAL sits at the 73.8% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($117.04 to $150.48).
ROARABLE RATING BRIEF • RQD 54/100 (D+)
✓ SEC XBRL & RQD VERIFIED
GRAL — GRAIL Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
GRAIL Inc. (GRAL) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $133.76 (-6.74% 1D, market capitalization $6.41B).
- Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -18.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -4.23%.
- Whale 13F & Options Flow (18/20) + Insider Conviction (6/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (9/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 7.26, Piotroski F-Score of 6/9, and Debt/Equity of 0.06x.
2. Business Model, Unit Margins & SEC Financial Trajectory
. Common Stock (GRAL) is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry, with a market capitalization of $7.1B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), GRAIL Inc. (GRAL) reported $147.2M in annual revenue (up from $125.6M in FY2024, +17.2% YoY) and -$408.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($93.1M revenue, -$1.47B net income) through FY2025, GRAL scaled operating cash flow to -$299.0M and free cash flow to -$299.9M, backed by $2.92B in total assets against $154.9M in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (D+ • RQD 54/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -4.23% and institutional whale pillar of 18/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $41.50 – $166.48 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical Specialities (Health Care), GRAL carries a macro regime beta of 1.00 and gross margin of —.
- Key Question #1: Can GRAL sustain or expand its -60.0% operating margin and -18.0% ROIC against Medical Specialities peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $147.2M and free cash flow of -$299.9M, how will capital allocation balance growth reinvestment against $154.9M in total debt?
- Key Question #3: How sensitive is GRAL's 22.0x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
GRAL Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for GRAIL Inc. (GRAL) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 21h ago
Grail (GRAL) vs Guardant Health (GH): Which is a Better Stock to Buy? Yahoo Finance report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Motley Fool • 1d ago
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years? The Motley Fool report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE CNBC • 1d ago
This buzzy biotech stock is up 60% this year. Cramer's advice on building a stake CNBC report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Investing.com • 1d ago
TD Cowen raises Grail stock price target to $180 on FDA outlook Investing.com report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 1d ago
Who Is Paying For GRAIL’s Cash Burn? Trefis report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingView • 1d ago
GRAIL, Inc. Stock 12‑Month Price Target Raised to $122.1, Implies 13% Downside TradingView report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance Singapore • 1d ago
GRAIL, Inc. (GRAL) stock price, news, quote and history Yahoo Finance Singapore report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Have Insiders Sold GRAIL Shares Recently? Simply Wall St report covering GRAIL Inc. (GRAL) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
GRAL Bull vs. Bear Conversation Board — What's Your Call at $133.76?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON GRAL 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $176.42 (+23.0%)
📌 Pinned Debate Institutional flow scores 18/20 and the balance sheet is supportive with Debt/Equity of 0.06 and an Altman Z-Score of 7.26.
The street is overcomplicating GRAIL Inc. (GRAL). Institutional flow scores 18/20 and the balance sheet is supportive with Debt/Equity of 0.06 and an Altman Z-Score of 7.26.. With an RQD score of 54/100 (D+) and Forensic Balance Sheet at 14/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $154.90.
EarningsSniper 🐂 BULL
@SkepticalCFA Shorting a 18/20 institutional whale-flow stock at $143.43 is dangerous when funds are rotating into Health Care.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $109.01 (-24.0%)
Spot @ $143.43 Negative ROIC of -18% and a negative FCF yield of -4.23% leave the cash engine scored 7/20 despite revenue growing to $147.2M.
Sitting on the sidelines or leaning short GRAL above $143.43. Negative ROIC of -18% and a negative FCF yield of -4.23% leave the cash engine scored 7/20 despite revenue growing to $147.2M.. Until Fundamental Cash Engine (7/20) and FCF yield (-4.23%) inflect higher, upside is capped near $166.48.